JPWO2020021541A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020021541A5 JPWO2020021541A5 JP2021503582A JP2021503582A JPWO2020021541A5 JP WO2020021541 A5 JPWO2020021541 A5 JP WO2020021541A5 JP 2021503582 A JP2021503582 A JP 2021503582A JP 2021503582 A JP2021503582 A JP 2021503582A JP WO2020021541 A5 JPWO2020021541 A5 JP WO2020021541A5
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- mitochondria
- human stem
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims 60
- 210000003470 mitochondria Anatomy 0.000 claims 33
- 238000000034 method Methods 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 4
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 4
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims 4
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims 4
- 238000011319 anticancer therapy Methods 0.000 claims 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108010030844 2-methylcitrate synthase Proteins 0.000 claims 2
- 108010071536 Citrate (Si)-synthase Proteins 0.000 claims 2
- 102000006732 Citrate synthase Human genes 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 210000002200 mouth mucosa Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000002407 ATP formation Effects 0.000 claims 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000009851 immunogenic response Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims 1
- 210000003098 myoblast Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000001626 skin fibroblast Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701783P | 2018-07-22 | 2018-07-22 | |
| US62/701,783 | 2018-07-22 | ||
| PCT/IL2019/050828 WO2020021541A1 (en) | 2018-07-22 | 2019-07-22 | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022519409A JP2022519409A (ja) | 2022-03-24 |
| JPWO2020021541A5 true JPWO2020021541A5 (https=) | 2022-07-29 |
| JP2022519409A5 JP2022519409A5 (https=) | 2022-07-29 |
| JP7633148B2 JP7633148B2 (ja) | 2025-02-19 |
Family
ID=69181398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503582A Active JP7633148B2 (ja) | 2018-07-22 | 2019-07-22 | 機能的ミトコンドリアで富化された幹細胞を用いたミトコンドリア増強療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210322485A1 (https=) |
| EP (1) | EP3823642A4 (https=) |
| JP (1) | JP7633148B2 (https=) |
| KR (1) | KR20210035829A (https=) |
| CN (1) | CN112601532A (https=) |
| AU (1) | AU2019311862B2 (https=) |
| BR (1) | BR112021001010A2 (https=) |
| CA (1) | CA3106188A1 (https=) |
| IL (1) | IL280162B2 (https=) |
| MX (1) | MX2021000954A (https=) |
| WO (1) | WO2020021541A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| US12551504B2 (en) | 2018-07-22 | 2026-02-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of pancreatic diseases |
| US12329781B2 (en) | 2018-07-22 | 2025-06-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| JP2021531288A (ja) | 2018-07-22 | 2021-11-18 | ミノヴィア セラピューティクス リミテッド | 眼疾患のミトコンドリア増強療法 |
| WO2020021536A1 (en) | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| JP7524157B2 (ja) | 2018-07-22 | 2024-07-29 | ミノヴィア セラピューティクス リミテッド | 脳疾患のミトコンドリア増強療法 |
| JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
| TWI789724B (zh) * | 2020-03-20 | 2023-01-11 | 台灣粒線體應用技術股份有限公司 | 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途 |
| CA3172402A1 (en) * | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
| WO2021224920A1 (en) * | 2020-05-05 | 2021-11-11 | Pluristem Ltd. | Methods and compositions for enrichment of target cells |
| AU2022211691A1 (en) * | 2021-01-25 | 2023-08-10 | Minovia Therapeutics Ltd. | Identification of mitochondria-enriched cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| EP2150117A4 (en) * | 2007-05-02 | 2011-10-05 | Mclean Hospital Corp | METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY |
| CN102266350A (zh) * | 2011-07-20 | 2011-12-07 | 黄必录 | 逆转干细胞衰老的方案 |
| CN102293178A (zh) * | 2011-08-28 | 2011-12-28 | 黄必录 | 使个体去衰老的方法 |
| CN103976935A (zh) * | 2014-05-28 | 2014-08-13 | 广州市白云区天芳化妆品厂 | 一种抗衰原液及其制备方法 |
| WO2016008937A1 (en) * | 2014-07-16 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the intercellular transfer of isolated mitochondria in recipient cells |
| CN106795490B (zh) * | 2014-09-11 | 2021-01-19 | 台湾粒线体应用技术股份有限公司 | 用线粒体特化细胞治疗神经退行性疾病的医药组合物 |
| IL299482B2 (en) * | 2015-02-26 | 2025-02-01 | Minovia Therapeutics Ltd | Mammalian cells are enriched with active mitochondria |
| WO2018088874A1 (ko) | 2016-11-14 | 2018-05-17 | 주식회사 파이안바이오테크놀로지 | 외래 미토콘드리아를 세포로 전달하는 방법 |
| EP3549589A4 (en) | 2016-11-30 | 2020-07-15 | Paean Biotechnology Inc. | PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA |
-
2019
- 2019-07-22 CN CN201980054078.2A patent/CN112601532A/zh active Pending
- 2019-07-22 KR KR1020217004453A patent/KR20210035829A/ko not_active Ceased
- 2019-07-22 JP JP2021503582A patent/JP7633148B2/ja active Active
- 2019-07-22 EP EP19840685.2A patent/EP3823642A4/en active Pending
- 2019-07-22 WO PCT/IL2019/050828 patent/WO2020021541A1/en not_active Ceased
- 2019-07-22 BR BR112021001010-6A patent/BR112021001010A2/pt not_active IP Right Cessation
- 2019-07-22 US US17/252,674 patent/US20210322485A1/en not_active Abandoned
- 2019-07-22 MX MX2021000954A patent/MX2021000954A/es unknown
- 2019-07-22 CA CA3106188A patent/CA3106188A1/en active Pending
- 2019-07-22 IL IL280162A patent/IL280162B2/en unknown
- 2019-07-22 AU AU2019311862A patent/AU2019311862B2/en active Active
-
2024
- 2024-08-27 US US18/817,206 patent/US20240415894A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519409A5 (https=) | ||
| US12605410B2 (en) | Mitochondria-enriched genetically engineered cells and uses thereof | |
| AU2005248352B2 (en) | Genetically engineered cells for therapeutic applications | |
| US20030091547A1 (en) | Platelet-derived growth factor protection of cardiac myocardium | |
| Bari et al. | Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation | |
| Der Sarkissian et al. | Optimizing stem cells for cardiac repair: current status and new frontiers in regenerative cardiology | |
| Redelman et al. | Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network | |
| US9688733B2 (en) | Method for treating spinal cord injury using HMGB1 fragment | |
| TW201130977A (en) | Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood | |
| JPWO2020021541A5 (https=) | ||
| MX2007008869A (es) | Metodo para proporcionar material celular facilmente disponible derivado de sangre de cordon, y una composicion de la misma. | |
| US20060110374A1 (en) | Method to accelerate stem cell recruitment and homing | |
| EP1771196B1 (en) | Ccr ligands for stem cell homing | |
| JPWO2020021540A5 (https=) | ||
| JPWO2020021539A5 (https=) | ||
| BRPI0620523A2 (pt) | método de aumentar o potencial de implante e de atração celular, método de preparar células para transplante em um sujeito, população de células e composição farmacêutica | |
| JPWO2020021537A5 (https=) | ||
| EP1697503B1 (en) | Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23 | |
| JPWO2021199032A5 (https=) | ||
| WO2003070083A2 (en) | Endothelial precursor cells for enhancing and restoring vascular function | |
| Waldner et al. | Immunomodulatory properties of adipose stem cells in vivo: Preclinical and clinical applications | |
| CN116987666A (zh) | 靶向sting通路制备治疗性nk细胞 | |
| US20240082365A1 (en) | Multidisciplinary treatment of chronic disease using regenerative cells and technologies | |
| Kochupillai et al. | stem celi: Its Evolving role in Cancer|-Management and Research | |
| US20090304650A1 (en) | Repair of the Bone Marrow Vasculature |